LGBT Cancer Project

Therapeutic Areas: Oncology | Gastroenterology | Family Medicine

Colorectal Cancer Clinical Trials

A listing of Colorectal Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

California

NEW

Research Center
Additional Locations California

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Colorado

NEW

Research Center
Additional Locations Colorado

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Connecticut

NEW

Research Center
Additional Locations Connecticut

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

District of Columbia

NEW

Research Center
Additional Locations District of Columbia

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Florida

NEW

Research Center
Additional Locations Florida

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Georgia

NEW

Research Center
Additional Locations Georgia

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Illinois

NEW

Research Center
Additional Locations Illinois

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Kentucky

NEW

Research Center
Additional Locations Kentucky

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Louisiana

NEW

Research Center
Additional Locations Louisiana

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Maine

NEW

Research Center
Additional Locations Maine

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Massachusetts

NEW

Research Center
Additional Locations Massachusetts

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Michigan

NEW

Research Center
Additional Locations Michigan

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Minnesota

NEW

Research Center
Additional Locations Minnesota

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Mississippi

NEW

Research Center
Additional Locations Mississippi

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Nebraska

NEW

Research Center
Additional Locations Nebraska

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Nevada

NEW

Research Center
Additional Locations Nevada

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

New Hampshire

NEW

Research Center
Additional Locations New Hampshire

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

New York

NEW

Research Center
Additional Locations New York

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

UPDATED

New York New York 10065

Patients are needed to participate in a clinical research study evaluating ADI-PEG 20 for the treatment of Advanced Gastrointestinal (GI) Malignancies

North Carolina

NEW

Research Center
Additional Locations North Carolina

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

North Dakota

NEW

Research Center
Additional Locations North Dakota

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Ohio

NEW

Research Center
Additional Locations Ohio

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Oregon

NEW

Research Center
Additional Locations Oregon

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Pennsylvania

NEW

Research Center
Additional Locations Pennsylvania

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Rhode Island

NEW

Research Center
Additional Locations Rhode Island

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

South Carolina

NEW

Research Center
Additional Locations South Carolina

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Tennessee

NEW

Research Center
Additional Locations Tennessee

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Texas

NEW

Research Center
Additional Locations Texas

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Virginia

NEW

Research Center
Additional Locations Virginia

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Washington

NEW

Research Center
Additional Locations Washington

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Australia

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Austria

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Belgium

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Canada

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Denmark

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

UPDATED

Copenhagen 2100

A Phase 1/Phase 2 clinical study for patients with Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer or Colorectal Cancer

UPDATED

Odense

Patients are needed to participate in a clinical research study of [6R] 5,10-methylenetetrahydrofolate, Fluorouracil and Oxaliplatin to evaluate Colorectal Neoplasm

Finland

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

France

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Germany

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Greece

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

UPDATED

Athens

Patients are needed to participate in a clinical research study of [6R] 5,10-methylenetetrahydrofolate, Fluorouracil and Oxaliplatin to evaluate Colorectal Neoplasm

UPDATED

Athens

Patients are needed to participate in a clinical research study of [6R] 5,10-methylenetetrahydrofolate, Fluorouracil and Oxaliplatin to evaluate Colorectal Neoplasm

UPDATED

Athens

Patients are needed to participate in a clinical research study of [6R] 5,10-methylenetetrahydrofolate, Fluorouracil and Oxaliplatin to evaluate Colorectal Neoplasm

UPDATED

Iráklion

Patients are needed to participate in a clinical research study of [6R] 5,10-methylenetetrahydrofolate, Fluorouracil and Oxaliplatin to evaluate Colorectal Neoplasm

Hungary

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Ireland

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Israel

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Italy

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy

Mexico

NEW

Research Center
Additional Locations International

An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy